CEDAR KNOLLS, N.J.,
May 21, 2019 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or the "Company")
(NASDAQ: MYOS), an advanced nutrition company and the owner of
Fortetropin®, a proprietary bioactive composition
derived from fertilized egg yolk that helps build lean muscle in
conjunction with resistance training, announced today that it will
present at the 9th Annual LD Micro Invitational at the
Luxe Sunset Boulevard Hotel in Los
Angeles being held June 3rd through
5th, 2019.
Joseph Mannello, Chief Executive
Officer of MYOS, is scheduled to present on Tuesday, June 4th at 3:40pm Pacific Time, and will be available to
meet with investors throughout the conference. Mr. Mannello will
present an overview of the Company with a focus on
Yolked® and MYOS Canine Muscle
Formula®, the Company's two core products that are
changing the way people think about the importance of muscle
health.
Mr. Mannello will be available on Tuesday, June 4 and Wednesday, June 5 for one-on-one meetings. To
schedule a meeting, please contact David
Scher at david@ldmicro.com or visit www.ldmicro.com for more
information.
About MYOS RENS Technology Inc.
MYOS RENS
Technology Inc. (MYOS), "The Muscle Company®", is a
Cedar Knolls, NJ-based advanced
nutrition company that develops and markets products that improve
muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size and lean body mass in conjunction with
resistance training. MYOS believes Fortetropin has the potential to
redefine existing standards of physical health and wellness. For
more information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the success of our products, including
Qurr®, Yolked®, MYOS Enteral
Nutrition Formula™ and MYOS Canine Muscle
Formula® , the success of our research and
development, the results of the clinical evaluation
of Fortetropin® and its effects, the
ability to enter into new partnership opportunities and the success
of our existing partnerships, the ability to generate revenue and
cash flow from sales of our products, the ability to increase our
revenue and gross profit margins, the ability to achieve a
sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in our filings with the Securities and Exchange
Commission. We undertake no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter
LeVay & Rose
Matthew Abenante, IRC, SVP
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-to-present-at-the-9th-annual-ld-micro-invitational-in-los-angeles-ca-300853493.html
SOURCE MYOS RENS Technology Inc.